ABL Bio (298380) Fundamentals 2026 — Revenue Analysis | SniperIQ
ABL Bio (298380) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩3.89T, trading at ₩69400.00 on the KOE. This SniperIQ fundamentals page covers ABL Bio's valuation, profitability (net margin -26.8%), revenue (₩79.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ABL Bio's market cap?
ABL Bio (298380) has a market capitalization of approximately ₩3.89T, trading at ₩69400.00 on the KOE. Market cap moves with the live share price.
What is ABL Bio's P/E ratio?
ABL Bio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 21.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ABL Bio?
ABL Bio runs a net profit margin of -26.8%, a gross margin of 86.6%, and an operating margin of -31.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ABL Bio generate?
ABL Bio reported revenue of ₩79.3B for fiscal year 2025, with net income of -₩37.9B and earnings per share (EPS) of -703.38. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ABL Bio pay a dividend?
ABL Bio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ABL Bio financially healthy?
ABL Bio carries a debt-to-equity ratio of 0.31x and a current ratio of 1.70x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ABL Bio a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ABL Bio (298380) the key facts are: market cap ₩3.89T, revenue ₩79.3B, 52-week range 67100-257500. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ABL Bio's full fundamentals live
Get ABL Bio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.